19911A G Mutation Analysis

ALUKARD vs Ro: eligibility rigor versus rapid telehealth flow

Ro and ALUKARD both serve telehealth demand, but their operating assumptions differ. Ro leans into broad, efficient pathway delivery; ALUKARD leans into...

Bone density and DEXA: who should test and when

Bone loss is usually silent until fracture. DEXA is one of the few tools that identifies risk early enough to act. This guide explains who should test, how...

Creatine, protein, and the two supplements that actually moved your labs

The supplement aisle sells 200 ingredients. The list with real human evidence and clinically meaningful effect sizes is shorter than five. Here's the honest...